{'fraction_non_alphanumeric': 0.020202020202020204, 'fraction_numerical': 0.0, 'mean_word_length': 5.608333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Nephroprotection and chemotherapy sensitivity impact of metformin during cisplatin therapy; an updated review

Chemotherapy has been accepted as the most common choice for cancer treatment. However, chemotherapy-induced toxicity and chemotherapy resistance are the two challenging barriers to the treatment. Metformin is a safe, inexpensive, and the first line drug to treat type II diabetes. It has also a significant anti-tumor effect with a selective cytotoxic efficacy on cancer stem cells. It also has renoprotective efficacy. The current study contributes to incorporating metformin to chemotherapeutic agents to develop treatment efficiency and reduce the chemotherapy-induced side-effects (such as toxicity and resistance) and also to benefit the nephroprotective impact of this drug.